Teva announces positive results from trial of AJOVY for migraine
Esme Needham | December 5, 2025 | News story | Research and Development | Neurology, Teva, migraine
Teva has announced positive results from the phase 4 PEARL study of AJOVY (fremanezumab), its treatment for chronic (CM) and episodic migraine (EM).
AJOVY is an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody administered as a subcutaneous injection. The PEARL study of AJOVY took place over 24 months, aiming to assess the impact of fremanezumab on migraine prevention in 1,140 patients living with either EM or CM.
Results from the study showed that primary and secondary endpoints had been met: over 66% of EM patients achieved a 50% reduction in monthly migraine days (MMD) during the first six months of treatment, as did 51.6% of CM patients. AJOVY also demonstrated sustained migraine prevention over the course of the 24 months.
The study also demonstrated the favourable tolerability and safety profiles of fremanezumab, with serious adverse effects relating to treatment being infrequent.
“These findings are consistent with the previously demonstrated safety profile from earlier PEARL analyses and provide additional reassurance for its use in clinical practice,” Dr Gürdal Sahin, Department of Clinical Sciences, Lund University, Sweden, said.
Migraine is a neurological disorder characterised by severe, sometimes days-long headaches, often accompanied by other symptoms such as light sensitivity and nausea. Patients with EM have up to 14 MMDs, while patients with CM have 15 or more.
Pinar Kokturk, vice president and head of medical affairs Europe at Teva, said: “PEARL has consistently demonstrated the clinical benefits of long-term fremanezumab use in patients burdened with debilitating migraine. This condition remains the second leading cause of disability worldwide, placing a significant burden on patients who face high disease impact and an urgent need for effective preventive treatment options.”
Teva is a global biopharmaceutical company with 37,000 employees across 57 markets.
Related Content
PharmNovo submits CTA for non-addictive neuropathic pain therapeutic
Swedish biotech PharmNovo has submitted a clinical trial application (CTA) to the Spanish health authorities …
NICE recommends migraine treatment for NHS use
The National Institute for Health and Care Excellence (NICE) has shared draft guidance recommending AbbVie’s …
Sanofi and Teva partner for development of inflammatory bowel disease treatment
Sanofi and Teva Pharmaceuticals have announced that they will collaborate for the co-development and co-commercialisation …
